Comparing 2 vs 3 Cycles of Neoadjuvant Immunotherapy for Esophageal Cancer
Author Information
Author(s): Gan Yi, Bao Ting, Tang Zhiwei, Cheng Chao, Zhu Haoshuai
Primary Institution: The First Affiliated Hospital, Sun Yat-sen University
Hypothesis
What is the optimal number of cycles of neoadjuvant immunotherapy combined with chemotherapy for patients with locally advanced esophageal squamous cell carcinoma?
Conclusion
Both 2 cycles and 3 cycles of neoadjuvant immunotherapy combined with chemotherapy are equally effective and safe for treating locally advanced esophageal squamous cell carcinoma.
Supporting Evidence
- The pathologic complete response rate was similar for both treatment groups.
- Postoperative complications were not significantly different between the two groups.
- Treatment-related adverse reactions were generally mild and comparable in both groups.
Takeaway
Doctors are trying to find out if giving 2 or 3 rounds of special cancer medicine before surgery works better, but it turns out both are about the same.
Methodology
Patients received either 2 or 3 cycles of neoadjuvant immunotherapy combined with chemotherapy followed by surgery, and their responses and outcomes were compared.
Potential Biases
Potential experimental bias due to the small number of patients and single-center design.
Limitations
The study was a single-center retrospective analysis with a relatively small sample size.
Participant Demographics
Patients aged 18-75 with locally advanced esophageal squamous cell carcinoma.
Statistical Information
P-Value
0.97
Statistical Significance
p>0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website